Completed PHASE1 INTERVENTIONAL 4-arm NCT05105607

A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of D-4517.2 After Subcutaneous Administration in Healthy Participants

A Phase 1 Open-Label Single-Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of D-4517.2 (Hydroxyl Dendrimer VEGFR Tyrosine Kinase Inhibitor) After Subcutaneous Administration in Healthy Volunteers

Sponsor: Ashvattha Therapeutics, Inc.

Conditions Diabetic Macular Edema Neovascular Age-related Macular Degeneration

Interventions D-4517.2

Updated 7 times since 2021 Last updated: Sep 19, 2022 Started: Jan 11, 2022 Primary completion: Aug 31, 2022 Completion: Aug 31, 2022

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1 trial investigates Diabetic Macular Edema and Neovascular Age-related Macular Degeneration and is currently completed. Ashvattha Therapeutics, Inc. leads this study, which shows 7 recorded versions since 2022 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Sep 2022 — Jul 2024 [monthly]

Completed PHASE1

Status: Recruiting → Completed
May 2022 — Sep 2022 [monthly]

Recruiting PHASE1
Mar 2022 — May 2022 [monthly]

Recruiting PHASE1

Status: Not Yet Recruiting → Recruiting

▶ Show 2 earlier versions

Feb 2022 — Mar 2022 [monthly]

Not Yet Recruiting PHASE1
Dec 2021 — Feb 2022 [monthly]

Not Yet Recruiting PHASE1

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Ashvattha Therapeutics, Inc.

Data source: Ashvattha Therapeutics, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Brisbane, Australia